Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability) (Stock code: 1681)

## **APPOINTMNET OF NON-EXECUTIVE DIRECTOR**

The board (the "Board") of directors (the "Directors") of Consun Pharmaceutical Group Limited (the "Company") is pleased to announce that Mr. LIN Sheng ("Mr. LIN") has been appointed as a non-executive Director of the Company with effect from 1 April 2016.

Mr. LIN, aged 41, joined Hony Capital Fund 2008, L.P. ("Hony Capital") in April 2003. He is mainly responsible for the medicine, medical services and telecom, media and technology industry research and investment. Mr. LIN has extensive experience in operations, product marketing and management and has extensive expertise in information technology.

Prior to joining Hony Capital, Mr. LIN worked with Lenovo Group Limited from April 2000 to April 2003, where he was responsible for personal digital assistant product line. He was responsible for strategic planning, market positioning, product design and business line operations. Mr. LIN acted as a non-executive director of Chinasoft International Limited which is listed on the main board of the Stock Exchange of Hong Kong Limited (the "Stock Exchange") (stock code:354) from July 2011 to April 2015.

Mr. LIN obtained a master degree in economics in July 1999, and also a dual bachelor degree in engineering physics and business administration from Tsinghua University in July 1997.

Save as disclosed above, Mr. LIN (i) has not held any other directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) does not hold any other position in the Company and its subsidiaries; (iii) does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) does not hold any other appointment or professional qualification.

Mr. LIN has entered into a letter of appointment with the Company to act as a non-executive Director for a specific term of three years from 1 April 2016, subject to the rotation requirements in accordance with the articles of association of the Company, and can be terminated by Mr. LIN or by the Company by giving not less than three months' notice in writing or in other ways in accordance with the letter of appointment. According to the articles of association of the Company, Mr. LIN will retire from office at the forthcoming annual general meeting and eligible for re-election. According to the letter of appointment with the Company, Mr. LIN will not receive any director's fee or remuneration for his position as a non-executive Director.

As at the date of this announcement, Mr. LIN does not have and is not deemed to have any interest or short position in the shares of the Company within the meaning of Part XV of the Securities and Future Ordinance.

There are no matters or information relating to the appointment of Mr. LIN that need to be brought to the attention of the shareholders of the Company or the Stock Exchange or to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange.

The Board would like to extend its welcome to Mr. LIN for joining the Board.

By order of the Board Consun Pharmaceutical Group Limited AN Yubao Chairman

Hong Kong, 31 March 2016

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian and Professor ZHU Quan as executive Directors; Mr. WANG Shunlong as non-executive Director; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHENG Xinxin as independent non-executive Directors.